GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fosun Pharmaceutical (Group) Co Ltd (SHSE:600196) » Definitions » Cash Flow for Lease Financing

Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Cash Flow for Lease Financing : ¥0 Mil (TTM As of Mar. 2024)


View and export this data going back to 1998. Start your Free Trial

What is Shanghai Fosun Pharmaceutical (Group) Co Cash Flow for Lease Financing?

Shanghai Fosun Pharmaceutical (Group) Co's Cash Flow for Lease Financing for the three months ended in Mar. 2024 was ¥0 Mil. Shanghai Fosun Pharmaceutical (Group) Co's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Mar. 2024 was ¥0 Mil.

Compared with last quarter (¥0 Mil in Dec. 2023 ), Shanghai Fosun Pharmaceutical (Group) Co's Cash Flow for Lease Financing remained the same in Mar. 2024 (¥0 Mil).

Shanghai Fosun Pharmaceutical (Group) Co Cash Flow for Lease Financing Historical Data

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fosun Pharmaceutical (Group) Co Cash Flow for Lease Financing Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow for Lease Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow for Lease Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Shanghai Fosun Pharmaceutical (Group) Co Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.


Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Fosun Pharmaceutical (Group) Co Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of Shanghai Fosun Pharmaceutical (Group) Co's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fosun Pharmaceutical (Group) Co Ltd (SHSE:600196) » Definitions » Cash Flow for Lease Financing
Comparable Companies
SZSE:000963 SZSE:002001 SZSE:000999 SHSE:600085 SHSE:688506 SHSE:600332 SZSE:000661 SZSE:000423 SHSE:600566 SHSE:600079 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ VTRS SZSE:000538 NBIX
Traded in Other Exchanges
SFOSF:USA 02196:Hong Kong 08HH:Germany
Address
No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233
Website
https://www.fosunpharma.com
Shanghai Fosun Pharmaceutical (Group) Co Ltd is a specialty and generic drug manufacturing company. Shanghai Fosun maintains five business segments, including Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. Most of the company's revenue is generated by its Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Headlines

No Headlines